Literature DB >> 28094767

Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease.

Sokrates Stein, Vera Lemos, Pan Xu, Hadrien Demagny, Xu Wang, Dongryeol Ryu, Veronica Jimenez, Fatima Bosch, Thomas F Lüscher, Maaike H Oosterveer, Kristina Schoonjans.   

Abstract

Hepatic steatosis is caused by metabolic imbalances that could be explained in part by an increase in de novo lipogenesis that results from increased sterol element binding protein 1 (SREBP-1) activity. The nuclear receptor liver receptor homolog 1 (LRH-1) is an important regulator of intermediary metabolism in the liver, but its role in regulating lipogenesis is not well understood. Here, we have assessed the contribution of LRH-1 SUMOylation to the development of nonalcoholic fatty liver disease (NAFLD). Mice expressing a SUMOylation-defective mutant of LRH-1 (LRH-1 K289R mice) developed NAFLD and early signs of nonalcoholic steatohepatitis (NASH) when challenged with a lipogenic, high-fat, high-sucrose diet. Moreover, we observed that the LRH-1 K289R mutation induced the expression of oxysterol binding protein-like 3 (OSBPL3), enhanced SREBP-1 processing, and promoted de novo lipogenesis. Mechanistically, we demonstrated that ectopic expression of OSBPL3 facilitates SREBP-1 processing in WT mice, while silencing hepatic Osbpl3 reverses the lipogenic phenotype of LRH-1 K289R mice. These findings suggest that compromised SUMOylation of LRH-1 promotes the development of NAFLD under lipogenic conditions through regulation of OSBPL3.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28094767      PMCID: PMC5272172          DOI: 10.1172/JCI85499

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  LRH-1-dependent glucose sensing determines intermediary metabolism in liver.

Authors:  Maaike H Oosterveer; Chikage Mataki; Hiroyasu Yamamoto; Taoufiq Harach; Norman Moullan; Theo H van Dijk; Eduard Ayuso; Fatima Bosch; Catherine Postic; Albert K Groen; Johan Auwerx; Kristina Schoonjans
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

2.  INTRACELLULAR TRANSPORT. Phosphatidylserine transport by ORP/Osh proteins is driven by phosphatidylinositol 4-phosphate.

Authors:  Joachim Moser von Filseck; Alenka Čopič; Vanessa Delfosse; Stefano Vanni; Catherine L Jackson; William Bourguet; Guillaume Drin
Journal:  Science       Date:  2015-07-23       Impact factor: 47.728

3.  Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways.

Authors:  Jessica L Yecies; Hui H Zhang; Suchithra Menon; Sihao Liu; Derek Yecies; Alex I Lipovsky; Cem Gorgun; David J Kwiatkowski; Gökhan S Hotamisligil; Chih-Hao Lee; Brendan D Manning
Journal:  Cell Metab       Date:  2011-07-06       Impact factor: 27.287

4.  A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans.

Authors:  Amy K Walker; René L Jacobs; Jennifer L Watts; Veerle Rottiers; Karen Jiang; Deirdre M Finnegan; Toshi Shioda; Malene Hansen; Fajun Yang; Lorissa J Niebergall; Dennis E Vance; Monika Tzoneva; Anne C Hart; Anders M Näär
Journal:  Cell       Date:  2011-10-27       Impact factor: 41.582

5.  Targeting of OSBP-related protein 3 (ORP3) to endoplasmic reticulum and plasma membrane is controlled by multiple determinants.

Authors:  Markku Lehto; Riikka Hynynen; Katja Karjalainen; Esa Kuismanen; Kati Hyvärinen; Vesa M Olkkonen
Journal:  Exp Cell Res       Date:  2005-09-06       Impact factor: 3.905

6.  Blockade of rapid versus prolonged extracellularly regulated kinase 1/2 activation has differential effects on insulin-induced gene expression.

Authors:  Adam B Keeton; Katherine D Bortoff; J Lee Franklin; Joseph L Messina
Journal:  Endocrinology       Date:  2005-02-24       Impact factor: 4.736

7.  The R-Ras interaction partner ORP3 regulates cell adhesion.

Authors:  Markku Lehto; Mikko I Mäyränpää; Teijo Pellinen; Pekka Ihalmo; Sanna Lehtonen; Petri T Kovanen; Per-Henrik Groop; Johanna Ivaska; Vesa M Olkkonen
Journal:  J Cell Sci       Date:  2008-02-12       Impact factor: 5.285

8.  SUMOylation-dependent LRH-1/PROX1 interaction promotes atherosclerosis by decreasing hepatic reverse cholesterol transport.

Authors:  Sokrates Stein; Maaike H Oosterveer; Chikage Mataki; Pan Xu; Vera Lemos; Rick Havinga; Claudia Dittner; Dongryeol Ryu; Keir J Menzies; Xu Wang; Alessia Perino; Sander M Houten; Frauke Melchior; Kristina Schoonjans
Journal:  Cell Metab       Date:  2014-08-28       Impact factor: 27.287

9.  Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1.

Authors:  Chikage Mataki; Benjamin C Magnier; Sander M Houten; Jean-Sébastien Annicotte; Carmen Argmann; Charles Thomas; Henk Overmars; Wim Kulik; Daniel Metzger; Johan Auwerx; Kristina Schoonjans
Journal:  Mol Cell Biol       Date:  2007-10-01       Impact factor: 4.272

10.  Genome-wide analysis of hepatic LRH-1 reveals a promoter binding preference and suggests a role in regulating genes of lipid metabolism in concert with FXR.

Authors:  Hansook Kim Chong; Jacob Biesinger; Young-Kyo Seo; Xiaohui Xie; Timothy F Osborne
Journal:  BMC Genomics       Date:  2012-02-01       Impact factor: 3.969

View more
  18 in total

1.  MRG15 orchestrates rhythmic epigenomic remodelling and controls hepatic lipid metabolism.

Authors:  Yuda Wei; Cheng Tian; Yongxu Zhao; Xiaojian Liu; Feng Liu; Shuang Li; Yanhao Chen; Yan Qiu; Zhuanghui Feng; Lanlan Chen; Tingting Zhou; Xiaoguang Ren; Chengwu Feng; Yan Liu; Wenqiang Yu; Hao Ying; Qiurong Ding
Journal:  Nat Metab       Date:  2020-05-04

Review 2.  Bridging the molecular and biological functions of the oxysterol-binding protein family.

Authors:  Antonietta Pietrangelo; Neale D Ridgway
Journal:  Cell Mol Life Sci       Date:  2018-03-13       Impact factor: 9.261

3.  Integrated Structural Modeling of Full-Length LRH-1 Reveals Inter-domain Interactions Contribute to Receptor Structure and Function.

Authors:  Corey D Seacrist; Georg Kuenze; Reece M Hoffmann; Brandon E Moeller; John E Burke; Jens Meiler; Raymond D Blind
Journal:  Structure       Date:  2020-05-19       Impact factor: 5.006

Review 4.  Signaling through non-membrane nuclear phosphoinositide binding proteins in human health and disease.

Authors:  Jamal M Bryant; Raymond D Blind
Journal:  J Lipid Res       Date:  2018-09-10       Impact factor: 5.922

5.  LRH-1 regulates hepatic lipid homeostasis and maintains arachidonoyl phospholipid pools critical for phospholipid diversity.

Authors:  Diego A Miranda; William C Krause; Amaury Cazenave-Gassiot; Miyuki Suzawa; Hazel Escusa; Juat Chin Foo; Diyala S Shihadih; Andreas Stahl; Mark Fitch; Edna Nyangau; Marc Hellerstein; Markus R Wenk; David L Silver; Holly A Ingraham
Journal:  JCI Insight       Date:  2018-03-08

Review 6.  Not So Slim Anymore-Evidence for the Role of SUMO in the Regulation of Lipid Metabolism.

Authors:  Amir Sapir
Journal:  Biomolecules       Date:  2020-08-06

7.  Enantiomer-specific activities of an LRH-1 and SF-1 dual agonist.

Authors:  Suzanne G Mays; Józef Stec; Xu Liu; Emma H D'Agostino; Richard J Whitby; Eric A Ortlund
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

8.  Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.

Authors:  Pui Y Lee-Law; Paula Olaizola; Francisco J Caballero-Camino; Laura Izquierdo-Sanchez; Pedro M Rodrigues; Alvaro Santos-Laso; Mikel Azkargorta; Felix Elortza; Maria L Martinez-Chantar; Maria J Perugorria; Patricia Aspichueta; Marco Marzioni; Nicholas F LaRusso; Luis Bujanda; Joost P H Drenth; Jesus M Banales
Journal:  J Hepatol       Date:  2020-09-17       Impact factor: 25.083

9.  Analysis of Time-Series Gene Expression Data to Explore Mechanisms of Chemical-Induced Hepatic Steatosis Toxicity.

Authors:  Alejandro Aguayo-Orozco; Frederic Yves Bois; Søren Brunak; Olivier Taboureau
Journal:  Front Genet       Date:  2018-09-18       Impact factor: 4.599

Review 10.  Neddylation: A Versatile Pathway Takes on Chronic Liver Diseases.

Authors:  Jiping Yao; Xue Liang; Yanning Liu; Min Zheng
Journal:  Front Med (Lausanne)       Date:  2020-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.